deferasirox has been researched along with Agranulocytosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bejaoui, M; Bonifazi, D; Ceci, A; Christou, S; Cosmi, C; Cuccia, L; Del Vecchio, GC; Della Pasqua, O; El-Beshlawy, A; Felisi, M; Filosa, A; Hassab, H; Kattamis, A; Kreka, M; Maggio, A; Origa, R; Putti, MC; Reggiardo, G; Sherief, L; Spino, M; Telfer, P; Tempesta, B; Tricta, F; Tsang, YC; Vitrano, A; Zaka, A | 1 |
| Kontoghiorghes, GJ | 1 |
1 trial(s) available for deferasirox and Agranulocytosis
| Article | Year |
|---|---|
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Topics: Administration, Oral; Adolescent; Agranulocytosis; Albania; Anemia, Sickle Cell; beta-Thalassemia; Cardiac Imaging Techniques; Child; Child, Preschool; Cyprus; Deferasirox; Deferiprone; Egypt; Erythrocyte Transfusion; Female; Ferritins; Greece; Hemoglobinopathies; Humans; Infant; Iron Chelating Agents; Iron Overload; Italy; Magnetic Resonance Imaging; Male; Patient Compliance; Treatment Outcome; Tunisia; United Kingdom; Urologic Diseases | 2020 |
1 other study(ies) available for deferasirox and Agranulocytosis
| Article | Year |
|---|---|
Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities.
Topics: Acute Kidney Injury; Agranulocytosis; Benzoates; Chelating Agents; Deferasirox; Humans; Iron; Product Surveillance, Postmarketing; Triazoles | 2007 |